BMJ Open Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada)

Jolyane Blouin-Bougie,¹ Nabil Amara,¹ Karine Bouchard,² Jacques Simard,³ Michel Dorval⁴

To cite: Blouin-Bougie J, Amara N, Bouchard K, *et al*. Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada). *BMJ Open* 2018;8:e016662. doi:10.1136/bmjopen-2017-016662

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-016662>).

Received 3 March 2017
Revised 27 November 2017
Accepted 9 January 2018

For numbered affiliations see end of article.

Correspondence to
PhD Candidate Jolyane Blouin-Bougie;
jolyane.blouin-bougie@fsa.ulaval.ca

ABSTRACT

Objectives To identify common and specific individual factors that favour or impede women's interest in and willingness-to-pay (WTP) for breast cancer susceptibility testing (BCST) and to identify the most impactful factors on both outcome measures.

Design and methods This study used a self-administered cross-sectional Web-based questionnaire that included hypothetical scenarios about the availability of a new genetic test for breast cancer.

Participants French-speaking women of the general population of Québec (Canada), aged between 35 and 69 years, were identified from a Web-based panel (2410 met the selection criteria, 1160 were reached and 1031 completed the survey).

Measures The outcomes are the level of interest in and the range of WTP for BCST. Three categories of individual factors identified in the literature were used as potential explanatory factors, that is, demographic, clinical and psychosocial.

Results Descriptive statistics indicated that the vast majority of sampled women are interested in BCST (90%). Among those, more than half of them are willing-to-pay for such a test (57%). The regression models pointed out several factors associated with both outcomes (eg, age, income, family history, locus of control-powerful others) and marginal effects were used to highlight the most impactful factors for each outcome.

Conclusion The results of this study provide a proxy of the readiness of women of the general population to use and to pay for BCST. They also offer insights for developing inclusive and specific strategies to foster informed decision-making and guide the services offered by health organisations corresponding to women's preferences and needs.

INTRODUCTION

Personalised medicine (PM) is an important growing area of research.¹ It is viewed as a significant driving economic sector² and an

Strengths and limitations of this study

- In accordance with the economic theory, this study proposes two ordered logit regression models allowing the testing of several explanatory factors of interest in and willingness-to-pay (WTP) for breast cancer susceptibility testing (BCST).
- This study also presents insights for developing inclusive and specific strategies that could support women's informed decision-making towards BCST and the range of service offerings by health organisations with regard to this test.
- Respondents' interest and WTP are measured using a hypothetical scenario; this may have led to an overestimation of the level of interest and the sum paid out-of-pocket in a realistic situation.
- Results presented in this study should be cautiously extrapolated to other neighbouring populations as interest in and WTP for genetic testing could greatly vary between populations, tests and methods used.

encouraging avenue to improve the delivery of healthcare services,^{3–5} notably through patient stratification approaches.^{5–7} The goal of PM might be notably achieved by the use of genetic tests. They sustain two main finalities of PM: one is preventive and the other is curative. Indeed, genetic tests could be indicated for healthy patients (ie, to assess ones' susceptibility to develop a disease and to provide risk management recommendations) or be used for the benefit of patients who are ill (ie, to specify diagnosis and prognosis and to support treatment decisions).⁸ This distinction is essential as the decision to be genetically tested is an individual one and may depend on whether the finality of

the genetic tests used is preventive or curative,⁹ that is to say that the person is healthy or ill.

Although the development of PM is seen as promising for the management of multiple diseases, breast cancer (BC) prevention remains of premier interest.^{6 10–12} It is worth noting that since the commercialisation of the BRCA1/2 mutation carrier test, many other genetic markers have been discovered. Indeed, several mutations (ie, rare genetic variations) on different genes and polymorphisms (ie, SNPs: common genetic variations present within particular subpopulations) are now known as BC susceptibility risk factors and can be detected simultaneously with recent technologies (eg, next-generation sequencing, panel-gene testing).^{13–17} Some genetic variants are moreover associated with greater risks than others. For instance, a mutation on *BRAC1*, *BRCA2*, *TP53* or *PTEN* confers a high risk, as a mutation on *CHECK2*, *PALB2* or *ATM* confers a moderate risk of developing BC.^{13 14 16} In this paper, we refer to carrier or predictive genetic tests, that lead to the identification of genetic variants that substantially increase BC risk, as breast cancer susceptibility tests (BCST). Besides the identification of at-risk women, BCST aim to provide suitable risk-management recommendations adapted to women's BC risk level and preferences (eg, type and interval of screening—mammograms or MRI—or consideration of prophylactic interventions—mastectomy or chemoprevention).^{8 18 19}

Given the increasing BC genetic knowledge base, stratifying healthy women's BC risk is viewed as an opportunity to adapt screening programmes to maximise benefits and minimise drawbacks for the general population and the healthcare systems in a foreseeable future.^{6 7 10 11 15 20 21} More research is however needed regarding variants that should be included in BCST targeting women of the general population.^{6 16} In addition, scepticism exists for 'whether publicly funded screening poses an acceptable burden on healthcare budgets'.²²

Up to now, however, these tests are generally offered to women by healthcare providers working in specialised clinical settings (eg, genetic clinics or hereditary cancer programmes), but are restricted to some particular group of patients.^{6 20 23} Otherwise, women may access some BCST via private companies and laboratories.^{24 25} Direct-to-consumer (DTC) genetic testing is however subject to arguments and contentions by researchers, professional societies and government agencies. Their preoccupations notably concerned the overriding healthcare professionals' support (ie, counselling services),^{19 25 26} the consumer's understanding of the test results and their implications (eg, worries, risk of discrimination, repercussions on family members),^{8 26 27} the tests' validity, the appropriateness of genetic markers assessed and the reliability of risk estimates, for which no evidence-based recommendations may have been yet established.^{16 25}

In that context, it might be important to get the pulse of the end-users, and this is the focus of this paper: it aims to gain insight into the readiness of women of the general population of Québec (Canada) to integrate and use genetic information for BC prevention. Before going further, we present an overview of BC prevention services and the use of BCST in Canada.

BC prevention in the Canadian context

Canada faces similar genetic services delivery challenges as other developed countries. One important particularity is the healthcare services' organisation scheme: services are provided and managed at a provincial level, but protection and well-being are overseen by the federation.²⁸ The extent of the funding of health services, including genetic testing or BC prevention risk-management strategies, covered by the provincial healthcare systems, thus falls under some federal regulations.²⁸ This may result in some discrepancies in the scope of services provided across provinces. For instance, *The Québec Breast Screening Program* invites all women aged between 50 and 69 years to have a mammogram every 2 years.²⁹ While other Canadian provinces offer similar free services, the age-range of the targeted women by screening programmes may slightly vary from province to province. In addition, while there is no risk stratification approach implemented in Canada, two Canadian provinces (Ontario and British Colombia) recently added some public healthcare facilities for high-risk women (ie, have a known mutation on BRAC 1 or 2, a strong family history or had prior chest radiation).

BC genetic services were available in genetic clinics shortly after the discovery of BRAC1 and BRAC2 in the mid-1990s in Canada.²³ It confers a well-established experience in managing the genetic risk of BC.¹⁵ However, only a small proportion of women currently have access to BCST, given the requirements to meet for service qualification, the complexity of the service trajectory⁶ and the limited number of healthcare providers authorised to order a genetic test.¹⁸ BCST are only offered to some patients with newly diagnosed BC and their relatives and to those with a strong BC family history.²³ The cost of these tests is covered for those who meet the criteria and have been referred by their provider to a genetic clinic for counselling. Women may thus have to go through a long and complex process, which often implies meeting various providers before testing and choosing a risk-management strategy that best fits their preferences and needs.^{6 18}

Furthermore, Canadian healthcare systems are known to be publicly funded, but there are private healthcare delivery channels (eg, private clinics, laboratories and companies, complementary private insurance market), and the health sector is facing continuous pressures for service privatisation.³⁰ Some BCST are also directly available from private companies, given the greater number of firms offering these tests to consumers. Even though the majority of those

societies are located in USA, their geographic situation is of minor importance: genetic tests can be bought via the Web.³¹

LITERATURE BACKGROUND

Notwithstanding the issues discussed above, previous studies have shown that women might demonstrate interest in and willingness-to-pay (WTP) for genetic testing as results may reduce uncertainty, offer some reassurance, guide life or family planning decisions and may be useful to other family members.^{9 24 27 32–34} The literature also underlined a great variability regarding populations (patients, general population, family members and so on) and health conditions when measuring levels of interest⁹ and estimating WTP values.³² This point supports the relevance of conducting a study for BCST in the particular context of Québec. Moreover, while the literature shows the existence of an association between interest in and cost of genetic tests for cancer susceptibility,^{27 35–38} there is no consensus on which one influences the other. Consistent with the economic theory,^{35 39} which supposes that a person's decision is a sequential process «where the decision of whether or not to consume a particular commodity is followed by the choice of how much to consume»,³⁹ we propose two regression models assessing (1) interest in BCST and (2) WTP for this type of tests among those interested. In addition, many studies attempting to assess interest in genetic testing identify predictors in an ad hoc manner without grounding them in theory, which leads to inconsistent findings.⁹ While the literature on WTP constitutes another stream of research, previous studies appeared to use numerous similar predictors.^{9 32} To deal with these issues, we identified a list of recurrent individual variables empirically tested in the context of cancer susceptibility testing. Inspired by the classifications of Sweeny *et al*⁹ and Lin *et al*,³² these variables were thereafter classified into three categories: demographic, medical and psychosocial (see online supplementary appendix 1 for the literature overview). Finally, previous study findings did not allow a detailed understanding of how preferences and WTP values vary according to individual factors.³² We then computed the marginal effects of individual factors associated with interest in and WTP for BCST. They are an informative means for summarising how change in a response is related to change in a covariate.^{40 41} This could be useful in targeting the most influential factors when designing interventions.

In light of the foregoing, the following section provides information on the method used to disentangle individual factors that influence interest in and WTP for BCST and to identify the most impactful factors on both outcomes from a sample of women living in Québec (Canada).

METHODS

Sample

The target population was made up of French-speaking women of the general population aged between 35 and 69 years, living in the province of Québec in Canada. The sample was selected from an internet panel maintained by a survey firm and weighted for age, regions and education level according to Statistics Canada census profiles.⁴² The sample size was calculated prior to data collection with a margin of error of 3% at a 95% CI.

Data collection

A cross-sectional Web-based survey developed from a literature review on genetic risk communication was used for this study. Respondents were asked to focus on their: general health state, BC clinical history and risk factors, level of literacy and numeracy, interest in and opinions regarding the use of BCST, reactions towards various life events, general psychological health state and demographic characteristics. The questionnaire was validated by experts in familial BC and pretested by the survey firm with 20 eligible women in February 2012. Their comments were collected in-person or by telephone; minor changes were made to the questionnaire to improve understanding. The questionnaire was afterward adapted for a Web platform and a survey link was sent by the firm to a sample of 2410 eligible women in March 2012. Three prize draws were offered to the participants: one of \$3000 and two of \$1000.

Measures

In order to avoid respondents' confusion, women were first advised as follows (freely translated from French) before presenting to them the items on interest and WTP: '*The next questions aim to better understand your interest in genetic tests used to assess the risk of developing a disease. The following scenarios are fictive. We will ask you how much you will be willing to pay for a genetic test. This question is only useful for the purpose of this research and does not mean that fees would be necessarily charged to get access to this test. Indeed, genetic tests requiring a simple blood testing are generally freely provided in Canada*'. A hypothetical scenario was then presented to women indicating that a new genetic test, now available on the market, could be used to assess their BC risk and to adapt their screening modalities should their risk level be higher than that of the general population. No specifications on the modalities under which this test could be offered or on the genes being assessed by this test were provided to the participants. Following that, respondents were asked to rank their level of interest in receiving this test on a 5-point Likert scale ('*Not at all*' to '*Extremely interested*'). Those having indicated to be at least '*Somewhat interested*' in BCST were thereafter asked how much they would be willing to pay for this test on a 6-point ordinal scale ('*Do not want to pay*' to '*Would pay more than \$1000*'). All respondents who had indicated to be '*Not interested at all*' were not asked to answer the WTP item. Detailed information regarding the scenario, operational measures of

outcomes and explanatory factors, including coding and main references, is presented in online supplementary appendix 2.

All clinical information needed to estimate the BC life-time risk of the respondents, according to the Gail Model parameters,⁴³ was collected for descriptive purposes. Some potential explanatory variables underlined in the literature were not included in the analysis for methodological concerns such as distribution of respondents or theoretical redundancy. However, no variables were removed from the models on the basis of low statistical significance because they were assumed to be of theoretical interest and expected to have some effect on women's interest in and WTP for BCST. Chosen measures were assessed with validated scales or in accordance with the scientific literature. The constructs with multiple-item scales (ie, loci of control, monitoring and anxiety) were evaluated with a principal components factor analysis; the unidimensionality criterion was satisfied. Cronbach's alpha (α) showed that items forming each of them were reliable. Finally, reported tolerance statistic values were all higher than 0.2 (online supplementary appendix 2); there were no multicollinearity concerns.⁴⁴

Statistical analysis

A posthoc power analysis was first conducted with G*Power 3.1.9 to ensure that we had an appropriate number of valid cases for statistical analyses to be performed and to detect a true effect when it exists.^{45 46} Second, descriptive and bivariate analyses were carried out to detail the characteristics of the sample and to assess statistical associations between outcome measures and individual factors believed to have an impact on interest and WTP for BCST (data not shown). Third, two ordered logit regression models^{47–49} were estimated accordingly to the assumption adopted in this study.^{50 51} They were used to investigate (1) women's interest in a BCST that may lead to more frequent screening should their risk level be higher than that of the general population with the original scale and then, for those at least 'Somewhat interested', (2) women's level of WTP for this genetic test with a measure capturing three levels of WTP (1= \$0, 2= 1 to \$100, 3= \$101 and over). Therefore, women who responded, in the first model, 'Not at all interested' in BCST were not included in the second analysis, that is, the model on WTP.

The ordered logit model uses an intermediate continuous variable Y^* (qualifications made by women regarding the dependent variable: INTER or WTP) in a

latent regression with a set of independent variables x_i . The range of the unobserved Y related to INTER and WTP was subdivided, respectively, in five and three adjacent intervals representing the classes of an observed variable, Z . Thus, it assumes a continuous process relating an unknown variable Y to independent variables x_i . For each dependent variable (INTER and WTP), the outcome of respondent i is represented by the latent index:

$$Y_i^* = \beta_1 X_{i1} + \dots + \beta_k X_{ik} + \varepsilon_i = \beta X + \varepsilon \quad (1)$$

where:

Y_i^* =the value of the index to the observation i

x =a vector of independent variables

β =the vector of parameters to be estimated

ε =the error term

Equation (1) cannot be estimated because Y^* is unobserved (latent index). However, we do observe the decision made by the respondents (the five and the three outcomes discussed above) as well as the x -vector. Thus, in order to estimate the models, the following assumptions are made:

$Z_i=1$ (Outcome 1) if $Y^* < \alpha_1$

$Z_i=2$ (Outcome 2) if $\alpha_1 \leq Y^* < \alpha_2$

...

$Z_i=n$ (Outcome n) if $Y^* \geq \alpha_{n-1}$

The ordering requires the thresholds ($\alpha_1, \alpha_2, \dots, \alpha_{n-1}$) to satisfy $\alpha_1 < \alpha_2 < \dots < \alpha_{n-1}$. Parameters β and the thresholds ($\alpha_1, \alpha_2, \dots, \alpha_{n-1}$) are simultaneously estimated using the maximum likelihood method, which maximises the probability of correct classifications. An application and a more detailed statistical description of the ordered logit models are presented by Amara *et al.*⁵² All those analyses were performed with SPSS V.13.0.⁵³ Finally, in order to assess the magnitude of the impact of explanatory variables on interest in and WTP for BCST, the marginal effects of the significant independent variables were ascertained with LIMDEP V.8.0 Econometrics Software Package.⁵⁴

RESULTS

Descriptive statistics

Overall, 1160 women were reached with the data collection procedure used. Among them, 40 clicked the questionnaire's link after the data collection period, 81 did not complete the questionnaire and 8 cancelled their panel subscription. The survey generated 1031 usable questionnaires for a net response rate of 43% (ie, when we consider all women who were not reached among eligible participants).

The sample was mostly composed of white educated women, in a civil union, and living in a large urban area (>100 000 inhabitants) (table 1). Moreover, most of the respondents overestimated both their personal BC life-time risk (mean=33.05%; SD=22.25%) and that of women in the general population (figure 1). However, according to the Gail Model parameters,⁴³ approximately 85% of the respondents had less than a 15% life-time risk of BC.

[†]The two models were estimated separately even though our approach might remind the Heckman's two-step sample selection procedure. This is mainly because the types of the dependent variables of our two models do not allow an appropriate use of Heckman's procedure. Indeed, 'the Heckman two-step estimator is specifically a probit model followed by a linear regression, and there is no simple analogue for the Heckman method for discrete choice models despite the logical appeal of the process'. Moreover, the use of models other than OLS in the second stage of Heckman's two-stage method is a frequent error in studies using this method.

Table 1 Demographic characteristics of the sample*

Respondents' characteristics	n=1031 (%)
Age	
35–49 years	503 (48.8)
50–69 years	528 (51.2)
Sys miss	0
Ethnicity	
White	977 (94.8)
Other	54 (5.2)
Sys miss	0
Marital status	
Widowed, divorced or separated	186 (18.1)
Single	152 (14.7)
Married or common-law	689 (66.9)
Sys miss	4 (0.4)
Education	
No diploma or secondary school	399 (38.7)
College or CEGEP diploma	265 (35.6)
University degree	367 (35.6)
Sys miss	0
Employment	
Full time	573 (55.6)
Part time	138 (13.4)
Retired	180 (17.5)
Student	15 (1.5)
Unemployed/not working	111 (10.8)
Sys miss	14 (1.4)
Household size	
1	135 (13.1)
2	403 (39.1)
3	192 (18.6)
4	181 (17.6)
5+	102 (9.9)
Sys miss	18 (1.7)
Location area	
Rural	146 (14.2)
Small urban	138 (13.4)
Medium urban	95 (9.2)
Large urban	636 (61.7)
Sys miss	16 (1.6)
Objective risk of BC†	
<15%	878 (85.2)
>15%	122 (11.8)
Sys miss	31 (3.0)
Perceived personal risk	
<15%	229 (22.2)
>15 %	555 (53.8)

Continued

Table 1 Continued

Respondents' characteristics	n=1031 (%)
Sys miss	247 (24.0)
Family history	
One or more first degree relative	146 (14.2)
No family history	869 (84.4)
Sys miss	16 (1.6)
Interest	
Not interested	93 (9.0)
Somewhat interested	113 (11.0)
Moderately interested	221 (21.4)
Very interested	389 (37.7)
Extremely interested	200 (19.4)
Sys miss	15 (1.5)
WTP	
Do not want to pay	250 (24.2)
Between \$1 and \$100	362 (35.1)
Between \$101 and \$250	153 (14.8)
Between \$251 and \$500	59 (5.7)
Between \$501 and \$1000	13 (1.3)
Over \$1000	3 (0.3)
Sys miss	191 (18.5)

*Sys miss category is the sum of the system missing data, and the option of answers 'do not know' and 'do not want to answer'.

†Calculated with the Gail model parameters (available online: <http://www.cancer.gov/bcrisktool/>). Absolute BC lifetime risk of a woman of the general population is of 11%–12%. However, risk prediction models used pure cumulative risk (ie, when no competing mortality risk exists), which is often higher than the absolute risk.⁸⁰

BC, breast cancer.

Descriptive statistics also revealed that 89% of the respondents were interested in BCST that may lead to more frequent screening, and 57% were willing to pay a certain amount of money to get the test. Furthermore, the one-way analysis of variance performed on ranked data indicates that there is at least one mean rank difference between ranges of WTP ($F(2,837)=83.992$; $P<0.000$). The Tamhane's posthoc analysis, used when homogeneity of variances are not assumed (Levenes' test: $F(2,837)=6802$; $P=0.001$), shows that the mean rank of interest in BCST significantly varies across the three ranges of WTP values (table 2): the more women are interested in BCST, the larger is the amount they are willing to pay for this tests.

Common explanatory factors of interest and WTP

The results of the estimation of the two ordered logit models are presented in table 3. For both models, the results suggest that having a BC family history rather than none, having a locus of control highly attributed to powerful others, being widowed, separated or divorced rather than being married or in a union and having a perception of health status as good instead of excellent

Figure 1 Respondents' distribution of reported BC life-time risk for a woman of the general population. Bar: Mean=41%, SD=18.6%, Nb of case=885, Sys miss=146. Vertical dashed line: BC life-time risk of a woman in the general population is of 11%–12% (correct answer). BC, breast cancer.

or very good, are all significantly associated with a higher interest in and higher WTP for BCST.

Conversely, having a high numeracy score compared with a low numeracy score, a household income of less than \$55 000 comparatively to a household income of \$75 000 and over and being aged under 50 rather than being aged 50 and over, are all significantly associated with a lower interest in and lower WTP for BCST. The variables biopsy, parity and education appeared to have no impact on either interest in or WTP for BCST.

Regarding marginal effects, the coefficients show that BC family history, household income and locus of

control-powerful others are the common explanatory variables that have the highest impact on women's interest in and WTP for BCST.

Specific factors associated with interest in BCST

Furthermore, there were several explanatory variables that were significantly associated only with interest in BCST. Indeed, being a high monitor compared with a low monitor and having a higher perceived risk of BC are significantly associated with a higher interest, while being highly optimistic rather than being poorly optimistic and having a locus of control highly attributed to chance are significantly associated with a lower interest for BCST.

More specifically, locus of control-powerful others, level of anxiety and BC family history stand with the highest marginal impact values, respectively of 0.441, 0.409 and 0.357. For the two former continuous variables, this implies that a positive relative change of 10% on these factors increases the level of women's interest in BCST by 4.41% and 4.09%. For the categorical variable, it means that interest in BCST is 35.7% greater among women with a family history of BC comparatively to those without.

Most impactful factors on WTP for BCST

For the WTP model, variables with the highest marginal effects are locus of control-powerful others (marginal effect=0.283), BC family history (marginal effect=0.208) and household income (marginal effect=-0.154, -0.103 and -0.079). These coefficients indicate that for a positive relative change of 10% on the locus of control-powerful others score, women's WTP for BCST would increase by 2.83%. This also means that WTP for BCST is 20.8% greater among women with a family history compared with those without and is as much as 15.4% lower among women with a household income of less than \$75 000 compared with those with an income of \$75 000 and over.

Table 2 Multiple mean group comparisons and posthoc analysis: level of interest according to range of WTP

Level of interest in BCST by range of WTP values*	Somewhat interested	Moderately interested	Very interested	Extremely interested	Total	Subsets of level of WTP† according to interest in BCST (mean rank)
Do not want to pay	68	84	72	26	250	421.76
Between \$0 and \$100	33	88	182	59	362	552.83
More than \$101	5	27	103	93	228	695.66
Total	106	199	357	178	840	

*All missing data, including options 'Do not want to answer' or 'Do not know', were coded as missing system data ('sys miss'). The 191 missing data on the WTP measure are distributed as follows: 15 missing system data on the Interest measures, 93 respondents 'Not at all interested' in BCST and 83 respondents having indicated to be at least 'Somewhat interested' in BCST, but having indicated 'Do not want to answer' or 'Do not know' on the WTP measure.

†Multiple means comparisons based on Tamhane's test: the posthoc analysis was performed following an one-way ANOVA on ranked data. The numbers in columns representing the subsets of level of WTP are mean rank of interest. All mean differences are significant at $P < 0.000$. ANOVA, analysis of variance; BCST, breast cancer susceptibility testing; WTP, willingness-to-pay.

Table 3 Estimated ordered logit models of factors affecting women's interest and WTP for BCST allowing more frequent screenings

Explanatory factors	Step 1		Step 2	
	Outcome interest (INTER) (1=Not interested at all to 5=Extremely interested)		Outcome Willingness-to-pay (WTP) (1=\$0; 2=\$1 to \$100; 3=\$101 and more)	
	Coefficients (β)	Marginal effect†	Coefficients (β)	Marginal effect†
Sociodemographic factors				
Age (AGE)	-0.215*	-0.054	-0.555***	-0.058
Household income				
Less than \$25,000 (INC1)	-0.667***	-0.101	-2.081***	-0.154
\$25,000 to \$54,999 (INC2)	-0.510***	-0.098	-1.083***	-0.103
\$55,000 to \$74,999 (INC3)	-0.074	–	-0.762***	-0.079
\$75,000 and over (INC4)	Benchmark		Benchmark	
Marital status				
Widowed-Separated-Divorced (WSD)	0.284*	0.027	0.381*	0.038
Single (SING)	0.184	–	0.201	–
Married or in union [MARUN]	Benchmark		Benchmark	
Education				
No diploma or secondary school diploma (EDUC1)	-0.074	–	-0.168	–
College or CEGEP diploma (EDUC2)	-0.218	–	-0.004	–
University diploma or degree (EDUC3)	Benchmark		Benchmark	
Medical factors				
Biopsy (BIOPSY)	-0.213	–	-0.358	–
Parity (PARITY)	0.060	–	0.131	–
Familial history (FAMHIS)	0.319**	0.357	0.396**	0.208
Psychological factors				
Optimism (OPTIMS)	-0.299*	-0.045	0.122	–
Monitoring (MO_MBSS)	0.464***	0.054	0.115	–
Health locus of control				
Powerful others (PHLC)	0.266***	0.441	0.211***	0.283
Internal (IHLC)	-0.040	–	-0.103	–
Chance (CHLC)	-0.190***	-0.244	-0.050	–
Anxiety (ANX_K6)	0.332***	0.409	0.213	–
Numeracy (NUM)	-0.421***	-0.055	-0.304*	-0.094
Perceived risk of BC (RISK)	0.070***	0.092	-0.002	–
Perceived health status				
Good (GOOD)	0.285**	0.047	0.513***	0.035
Fair-Bad (FAIRBAD)	0.428	–	0.378	–
Excellent -Very good [EXVER]	Benchmark		Benchmark	
Measures of goodness of fit‡				
Ancillary parameters				
Threshold 1	-1.434		-2.346	
Threshold 2	-0.248		-0.153	

Continued

Table 3 Continued

Explanatory factors	Step 1		Step 2	
	Outcome interest (INTER) (1=Not interested at all to 5=Extremely interested)		Outcome Willingness-to-pay (WTP) (1=\$0; 2=\$1 to \$100; 3=\$101 and more)	
	Coefficients (β)	Marginal effect†	Coefficients (β)	Marginal effect†
Threshold 3	0.962			
Threshold 4	2.728			
Number of cases	635		544	
Likelihood ratio ($df = 21$)	65.861		60.961	
Nagelkerke R^2 (Pseudo R^2)	0.104		0.120	
Percentage of correct predictions	50.23%		53.31%	

*, ** and *** indicate that variable is significant at 10%, 5% and 1%, respectively. Given the nature of the variables assessed and the mixed findings reported for almost all of them in the literature on cancer susceptibility testing, and the number of valid cases included in the analysis, we used three commonly used alpha thresholds to provide to readers more precisions on the significance of our results.⁸¹⁻⁸³

†For continuous variables, values of marginal effect represent the variation in percentage on the outcome for 1% positive relative change in the corresponding explanatory factor, while for categorical variables, marginal effect values indicate the variation in percentage on the outcome if the sub sample of respondents would share the same characteristic of those of the reference category.

‡The computation of the measures of goodness of fit of the two models leads to the conclusion that they were well behaved. This is indicated by the thresholds in increasing order ($\alpha_1 < \alpha_2 < \alpha_3$) and the χ^2 statistics that were much larger than the critical value ($P < 0.000$) in both models. The 'predictive power' of the models and the Nagelkerke R^2 values also appeared to be acceptable for such qualitative models.

BCST, breast cancer susceptibility testing; WTP, willingness-to-pay.

DISCUSSION

This study provides evidence on the common and specific individual factors associated with interest in and WTP for BCST that may allow for more frequent screening if one's BC risk level is higher than that of the general population. The econometric exercise revealed that seven individual factors were found significantly associated with both interest in and WTP for BCST: age, household income, marital status, family history, locus of control (powerful others), perceived health status and numeracy, while five factors were found significantly associated only with interest in BCST: optimism, monitoring, locus of control (chance), anxiety and perceived risk. A quick comparison of our study results with the ones of the literature is available in online supplementary appendix 1.

The results of this study have limitations that inform the interpretation of its results and suggest further research. First, our findings might be considered as representative of French-speaking women aged between 35 and 69 years living in Québec (Canada), but should be cautiously extrapolated to other similar or neighbouring populations. Previous studies called attention to the great variability regarding interest level and WTP estimates across populations studied for genetic testing in general.^{9 32} Second, our response rate may seem low (43%), but several prior studies on interest in and WTP for genetic testing obtained comparable response rates.^{55 56} Third, self-reported data like those used in this study are subject to a social desirability bias. Fourth, as done in previous studies,^{27 34 35 57} a hypothetical scenario was used in this study. Then, reported results on the degree of interest in and WTP for BCST

should not be taken as an objective uptake measure of testing, but as a measure of intention.^{9 27 38} Other studies have also demonstrated that revealed measures of WTP overestimate the sum paid out-of-pocket in a realistic situation.^{27 34 58} Fifth, different measures of WTP or elicitation techniques to value BCST in the general population in Québec should be used to confirm our findings. Indeed, the literature revealed discrepancies between studies of WTP estimates according to measures and methods employed for similar tests.³² Moreover, we used only one item to measure WTP on an ordered scale. This is among the several ways used by authors to measure WTP,³³ even though many studies opted for double or multiple bidding items.⁵⁹ Furthermore, it has been demonstrated that each of the measurement methods has its strengths and limitations, but above all, the level of accuracy gained by the econometric model used afterward is negligible in the case of sample sizes like ours ($n=1031$).⁵⁹ Finally, as this paper only focused on individual factors, future studies should investigate other potential factors associated with interest in and WTP for BCST, like those at the organisational, social or environmental level and should more explicitly ground the explanatory variables in theoretical frameworks. Other aspects could contribute to the choice of being genetically tested, and this may vary by type of genetic test and the purpose of its use.^{9 32} This also has implications in terms of results' interpretation. Significance and effects of individual factors discussed above are subject to change if other contributing factors to the overall predictive power would be added in the respective equations of INTER and WTP modelling.⁴¹

Potential implications

The findings of this study first provide a proxy for the readiness of women of the general population of Québec to get genetically tested for BC susceptibility and the amount they expect to be acceptable to pay for such services in private settings, given the formulation of the scenario. While we did not assess various payments vehicles, our results may provide insights (1) on the willingness of the general population to make accessible BCST to more women in the context of the current publicly funded system; (2) on their degree of openness towards a new copayment method for such a test or (3) on the setting of insurance copayments, if any, in some situations.^{22 32} As the results show, a majority of the women were at least somewhat interested in BCST (~90%), and more than half were willing to pay a certain amount of money for such a test. Indeed, nearly 35% of the women of our sample would pay up to \$100, 15% up to \$250 and 7% more than \$250. However, a great proportion of them was not willing to pay (24%) or did not provide information on the survey item assessing their WTP for BCST (18% of missing data, which includes 9% of respondents 'Not interested at all' in BCST). Overall, this suggests that the women of Québec have mitigated enthusiasm towards BCST if they have to pay for it, which is consistent with another study led in the Canadian context.³⁷ While it may reflect some important values of Canadian citizens that are embodied in the Medicare system,³⁰ studies led in private healthcare systems reported similar findings.^{35 56}

Second, the results suggest that many psychosocial factors are associated with women's interest in and WTP for BCST. Indeed, in line with the findings of several prior studies on cancer susceptibility testing,^{35 60–63} our results reveal that the higher the women's BC risk perceptions are, the higher their level of interest in BCST is. It is worth mentioning, however, that women's interest in BCST should be analysed in light of another important finding: women greatly overestimated both their personal lifetime risk of developing BC and that of women of the general population. Similar results were also found in other populations.^{64–66} This overestimation may be due to a lack of knowledge, a low level of numeracy or otherwise unrealistic worries about BC.^{64–66} In addition, as reported by other studies,^{27 56} more anxious, less optimistic women and those with poor numeracy skills are more interested in BCST and thus, will probably more extensively use such services. This may suggest that some moderating psychosocial variables might influence the women's decision process to get tested or not. Moreover, it could result in a biased level of interest in and WTP for BCST.

Previous studies have also reported an association between perceived control or risk tolerance and interest in and WTP for cancer susceptibility testing.^{34 35 67} Our results support this finding and indicate that one of the most impactful factors on women's interest and WTP is the external health locus of control-powerful others. It implies that a woman who believes that others she considers as experts are largely responsible for her

health is more interested in and willing to pay for BCST. As underlined in studies on BC screening,^{68 69} this result suggests that healthcare providers' recommendations, public health or for-profit organisations' communication campaigns or marketing strategies might have an impact on some women's interest in and WTP for BCST. Beyond that, private companies' DTC advertising efforts may take advantage of actual consumers' emotional concerns or knowledge deficit in genetics.^{25 56} These companies should thus be fully encouraged to incorporate adapted modes of communication and provide personalised risk counselling to consumers, instead of their current approach of 'one-size-fits-all'.²⁵

These facts lead, as others proposed,^{9 27 35} to reiterate the necessity of putting a stronger emphasis on popular education and of developing educational material towards genetics and the notion of risk to ensure that the choice of getting tested for BC susceptibility is made following an informed decision-making process and based on more objective and realistic risk perceptions of BC. As a starting point, we suggest that some lessons learnt from public health and charity organisation messages and decision aids (eg, information from leaflet or web page, communication campaigns and other health promotion strategies) about cancer screening^{68 69} may serve as a building block for the dissemination of BCST information among the general population. The literature on BC risk communication may also provide important cues on the most comprehensive ways genetic risk should be transmitted to women of the general population.^{70 71} Interventions improving knowledge and awareness, as well as fostering objective BC risk evaluation, have the potential to improve ethical and informed decision-making,^{68 69} but may also slightly decrease interest in and WTP for BCST.^{9 35 36}

Third, the findings of this study may help health organisations, either private or public, to better define the range of service offerings or to adjust service delivery modalities to public or consumers' preferences and needs.^{35 36} For instance, following results discussed previously on perceived risk, numeracy, anxiety or optimism, it seems that reassurance, support and education as provided in highly specialised services of genetic counselling are important elements to be adapted for public healthcare settings—such as in the case of the implementation of a BC risk stratification programme—and to be provided by private companies selling BCST directly to consumer in order to minimise drawbacks for women (eg, anxiety, miscomprehensions and so on).^{25 35 56}

Finally, study results related to some medical and demographic factors could provide insightful paths of action for developing strategies targeting specific subgroups of women in the population. For instance, women with a BC family history are more interested in and willing to pay for BCST. Several studies have reported similar findings.^{9 32 61 62 72 73} They are also at greater risk of BC.⁷⁴ Given their BC family history and their experience with this disease, some of them may be more aware of their increased BC risk. In turn, they may attribute more value

and get more benefits from such testing than those without family history. Improving BCST access to those women, as other Canadian provinces did by adding public healthcare facilities, might be relevant. It could help to ensure that their interest and willingness to take the test is based on an informed decision instead of the results of biased self-(over)estimations of BC risk.

Moreover, paying more attention to young women (35–49 years old) in clinical encounters could be a winning strategy. It might contribute to the demystification of the notion of risk and the genetic component of BC into the next generation of women who will be likely invited into BC screening or stratification programmes. Furthermore, familial and genetic BC are often developed at a younger age than the sporadic form of BC.⁷⁵ So, this could lead to recommendations of early risk-management strategies for young women at greater risk of BC, who are less interested in and attribute less value to BCST, in taking into consideration their specificities and potential needs (eg, family-planning decisions).^{76 77}

In addition, the study's results indicate that interest in and WTP for BCST increased with income. Even if this is in line with the budget constraint function of the economic theory³⁵ and that previous studies pointed out similar findings,^{22 32 35} inconsistent results are reported by a recent systematic review on interest in genetic testing.⁹ Likewise, some authors found mixed results regarding its association with the socioeconomic status.^{35 60 61} As this concept reflects more broadly family or household resources, including education, employment, goods and revenues, one hypothesis may be that some confounding or moderating variables are involved in the decision-making process of women opting or not for BCST. Nevertheless, our results suggest that interventions designed for women from lower-resourced neighbourhoods or targeting physicians with a large panel of women with low income could prevent some inequalities in the uptake of BCST (eg, health or life insurance and employment discrimination, limited access to health services given the cost (if the test is pay-out-of-pocket or partially reimbursed by private insurance) or in the way the risk is assessed, ie, the risk factors considered, notably age, ethnicity and family history).^{78 79}

CONCLUSION

This study disentangles common and specific individual determinants of interest in and WTP for BCST among women of the general population of Québec (Canada). It also presents insights for developing inclusive and specific strategies that could support women's informed decision-making towards BCST and the range of service offerings by health organisations with regard to this test. For managers and decision-makers involved in BC prevention, thinking to adjust or to extend BC genetic services and desiring to adapt them to public preferences and needs, this study highlights two ways of proceeding that could be profitable from a social and economic point

of view. The first is to develop interventions targeting the whole population, such as health promotion campaigns, by focusing on the psychosocial factors, given the number of significant factors explaining interest in and WTP for BCST. The second is to tailor interventions to particular subpopulations by considering the most impactful factors associated with interest in and WTP for BCST, such as family history backgrounds or strata of household income.

Author affiliations

¹Department of Management, Université Laval, Québec, QC, Canada

²Centre des maladies du sein Deschênes-Fabia, Centre de recherche du CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, Québec, QC, Canada

³Faculty of Medicine, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada

⁴Faculty of Pharmacy, Centre de recherche du CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, Québec, QC, Canada

Acknowledgements The authors want to thank the reviewers for their insightful comments and suggestions on this manuscript.

Contributors All authors were responsible for the project design (led by JS and MD). MD and KB were in charge of the survey development and the data collection. JB-B and NA made the data analysis and drafted the preliminary version of the manuscript. All authors contributed to results' interpretation, commented on drafts and agreed on the final version of this article.

Funding This research was supported the Canadian Institutes of Health Research as a part of the CIHR Team in Familial Risks of Breast Cancer Grant (CRN-8752-1), and the PERSPECTIVE project, funded by The Government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the Ministère de l'Économie, de la Science et de l'Innovation du Québec through Genome Québec, and the Québec Breast Cancer Foundation.

Competing interests None declared.

Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

Ethics approval This study was approved by the Comité d'éthique et de la recherche du CHU de Québec-Université Laval (#2012-1584/2012-HSS-300-05).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Khoury MJ, Coates RJ, Fennell ML, *et al.* Multilevel research and the challenges of implementing genomic medicine. *J Natl Cancer Inst Monogr* 2012;2012:112–20.
2. Health Leaders Media - a division of HCPro Inc. In collaboration with price water house cooper. The impact of personalized medicine today Massachusetts, United-States2010. <http://www.healthleadersmedia.com/breakthroughs>
3. Welch BM, Kawamoto K. Clinical decision support for genetically guided personalized medicine: a systematic review. *J Am Med Inform Assoc* 2013;20:388–400.
4. Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. *Mol Cancer Res* 2010;8:1175–87.

5. Gouvernement du Canada - Canadian Institutes of Health Research. Personalized medicine 2015. <http://www.cihr-irsc.gc.ca/e/43627.html>
6. Foulkes WD, Knoppers BM, Turnbull C. Population genetic testing for cancer susceptibility: founder mutations to genomes. *Nat Rev Clin Oncol* 2016;13:41–54.
7. Dent T, Jbilou J, Rafi I, et al. Stratified cancer screening: the practicalities of implementation. *Public Health Genomics* 2013;16:94–9.
8. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. *Transl Res* 2009;154:277–87.
9. Sweeny K, Ghane A, Legg AM, et al. Predictors of genetic testing decisions: a systematic review and critique of the literature. *J Genet Couns* 2014;23:263–88.
10. Burton H, Jackson C, Abubakar I. The impact of genomics on public health practice. *Br Med Bull* 2014;112:37–46.
11. Chowdhury S, Dent T, Pashayan N, et al. Incorporating genomics into breast and prostate cancer screening: assessing the implications. *Genet Med* 2013;15:423–32.
12. Evans DG, Donnelly LS, Harkness EF, et al. Breast cancer risk feedback to women in the UK NHS breast screening population. *Br J Cancer* 2016;114:1045–52.
13. Evans DG, Howell A. Can the breast screening appointment be used to provide risk assessment and prevention advice? *Breast Cancer Res* 2015;17:841.
14. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. *Science* 2014;343:1466–70.
15. Howe R, Miron-Shatz T, Hanoch Y, et al. Personalized medicine through SNP testing for breast cancer risk: clinical implementation. *J Genet Couns* 2015;24:744–51.
16. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med* 2015;372:2243–57.
17. Michailidou K, Lindström S, Dennis J, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature* 2017;551:92–4.
18. Amara N, Blouin-Bougie J, Jbilou J, et al. The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes. *Fam Cancer* 2016;15:1–17.
19. O'Daniel JM. The prospect of genome-guided preventive medicine: a need and opportunity for genetic counselors. *J Genet Couns* 2010;19:315–27.
20. Howell A, Astley S, Warwick J, et al. Prevention of breast cancer in the context of a national breast screening programme. *J Intern Med* 2012;271:321–30.
21. Onega T, Beaber EF, Sprague BL, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. *Cancer* 2014;120:2955–64.
22. Kilambi V, Johnson FR, González JM, et al. Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. *Value Health* 2014;17:838–45.
23. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. *Nat Rev Clin Oncol* 2010;7:702–7.
24. Goldsmith L, Jackson L, O'Connor A, et al. Direct-to-consumer genomic testing: systematic review of the literature on user perspectives. *Eur J Hum Genet* 2012;20:811–6.
25. Bellcross CA, Page PZ, Meaney-Delman D. Direct-to-consumer personal genome testing and cancer risk prediction. *Cancer J* 2012;18:293–302.
26. Zimmern RL, Khoury MJ. The impact of genomics on public health practice: the case for change. *Public Health Genomics* 2012;15:118–24.
27. Graves KD, Peshkin BN, Luta G, et al. Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing. *Public Health Genomics* 2011;14:178–89.
28. Kristofferson U, Schmidtke J, Cassiman J. *Quality issues in clinical genetic services*: Springer, 2010.
29. Gouvernement du Québec. Québec Breast Cancer Screening Program 2017. <http://sante.gouv.qc.ca/en/programmes-et-mesures-daide/programme-quebecois-de-depistage-du-cancer-du-sein-pqdc/> (accessed 12 Nov 2017).
30. Loeppky R. Canada, health and historical political economy. *Journal of Australian Political Economy* 2014;73:172–99.
31. Ries N, Einsiedel E. Test génétiques offerts directement aux consommateurs via Internet – Enjeux et options stratégiques. In: *Mémoires stratégiques*. Génome Canada: Répercussions sociétales et politiques publiques, 2010:9.
32. Lin PJ, Cangelosi MJ, Lee DW, et al. Willingness to pay for diagnostic technologies: a review of the contingent valuation literature. *Value Health* 2013;16:797–805.
33. Kopits IM, Chen C, Roberts JS, et al. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. *Genet Test Mol Biomarkers* 2011;15:871–5.
34. Neumann PJ, Cohen JT, Hammit JK, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. *Health Econ* 2012;21:238–51.
35. Bosompra K, Ashikaga T, Flynn BS, et al. Psychosocial factors associated with the public's willingness to pay for genetic testing for cancer risk: a structural equations model. *Health Educ Res* 2001;16:157–72.
36. Matro JM, Ruth KJ, Wong YN, et al. Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing. *J Genet Couns* 2014;23:1002–11.
37. Ries NM, Hyde-Lay R, Caulfield T. Willingness to pay for genetic testing: a study of attitudes in a Canadian population. *Public Health Genomics* 2010;13:292–300.
38. Lacour RA, Daniels MS, Westin SN, et al. What women with ovarian cancer think and know about genetic testing. *Gynecol Oncol* 2008;111:132–6.
39. Saha A, Capps O, Byrne PJ. Calculating marginal effects in dichotomous - continuous models. *Appl Econ Lett* 1997;4:181–5.
40. Hanmer MJ, Ozan Kalkan K. Behind the curve: clarifying the best approach to calculating predicted probabilities and marginal effects from limited dependent variable models. *Am J Pol Sci* 2013;57:263–77.
41. Mood C. Logistic Regression: why we cannot do what we think we can do, and what we can do about it. *Eur Sociol Rev* 2010;26:67–82.
42. Statistics Canada. *Enquête sur la santé dans les collectivités canadiennes (ESSC)*, 2010:417.
43. Gail MH, Brinton LA, Byrnie DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989;81:1879–86.
44. Field A. *Discovering statistics using IBM SPSS statistics*: Sage, 2013.
45. Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. *Behav Res Methods* 2009;41:1149–60.
46. Portney LG, Watkins MP. *Foundations of clinical research: applications to practice*. 3rd edn. Philadelphia, USA: FA Davis Co, 2015.
47. Aldrich JH, Nelson FD, probability L. *Linear probability, logit, and probit models*: Sage, 1984.
48. Greene WH, Hensher DA. *Modeling ordered choices: a primer*. 1st edn: Cambridge University Press, 2010.
49. Fullerton AS. A conceptual framework for ordered logistic regression models. *Sociol Methods Res* 2009;38:306–47.
50. Bushway S, Johnson BD, Slocum LA. Is the magic still there? The use of the heckman two-step correction for selection bias in criminology. *J Quant Criminol* 2007;23:151–78.
51. Dubin JA, Rivers D. Selection bias in linear regression, logit and probit models. *Sociol Methods Res* 1989;18:360–90.
52. Amara N, Ouimet M, Landry REJean. New evidence on instrumental, conceptual, and symbolic utilization of university research in government agencies. *Sci Commun* 2004;26:75–106.
53. SPSS Inc. SPSS for Windows. Version 13.0. Chicago, USA: SPSS Inc. 2004.
54. Greene WH. *LIMDEP: Version 8.0: Econometric Modeling Guide*: Econometric Software, 2002.
55. Neumann PJ, Hammit JK, Mueller C, et al. Public attitudes about genetic testing for Alzheimer's disease. *Health Aff* 2001;20:252–64.
56. Miron-Shatz T, Hanoch Y, Doniger GM, et al. Subjective but not objective numeracy influences willingness to pay for BRCA1/2 genetic testing. *Judgment and Decision Making* 2014;9:152–8.
57. Michael F, Drummond MJS, Claxton K, et al. *Methods for the economic evaluation of health care programmes*. 4th edn, 2015.
58. Cookson R. Willingness to pay methods in health care: a sceptical view. *Health Econ* 2003;12:891–4.
59. Calia P, Strazzera E. Bias and efficiency of single versus double bound models for contingent valuation studies: a Monte Carlo analysis. *Appl Econ* 2000;32:1329–36.
60. Bosompra K, Flynn BS, Ashikaga T, et al. Likelihood of undergoing genetic testing for cancer risk: a population-based study. *Prev Med* 2000;30:155–66.
61. Bunn JY, Bosompra K, Ashikaga T, et al. Factors influencing intention to obtain a genetic test for colon cancer risk: a population-based study. *Prev Med* 2002;34:567–77.
62. Kinney AY, Croyle RT, Dudley WN, et al. Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large African-American kindred with a BRCA1 mutation. *Prev Med* 2001;33:543–51.
63. Reitz F, Barth J, Bengel J. Predictive value of breast cancer cognitions and attitudes toward genetic testing on women's

- interest in genetic testing for breast cancer risk. *Psychosoc Med* 2004;1:Doc03.
64. Rutherford EJ, Kelly J, Lehane EA, *et al.* Health literacy and the perception of risk in a breast cancer family history clinic. *Surgeon* 2016.
 65. MacTiernan A, Fritschi L, Slevin T, *et al.* Public perceptions of cancer risk factors: a Western Australian study. *Health Promot J Austr* 2014;25:90–6.
 66. Fehniger J, Livaudais-Toman J, Karliner L, *et al.* Perceived versus objective breast cancer risk in diverse women. *J Womens Health* 2014;23:420–7.
 67. Nordin K, Björk J, Berglund G. Factors influencing intention to obtain a genetic test for a hereditary disease in an affected group and in the general public. *Prev Med* 2004;39:1107–14.
 68. Hersch JK, Nickel BL, Ghanouni A, *et al.* Improving communication about cancer screening: moving towards informed decision making. *Public Health Res Pract* 2017;27.
 69. Vrinten C, McGregor LM, Heinrich M, *et al.* What do people fear about cancer? A systematic review and meta-synthesis of cancer fears in the general population. *Psychooncology* 2017;26:1070–9.
 70. Dorval M, Bouchard K, Chiquette J, *et al.* A focus group study on breast cancer risk presentation: one format does not fit all. *Eur J Hum Genet* 2013;21:719–24.
 71. Julian-Reynier C, Welkenhuysen M, Hagoel L, *et al.* Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. *Eur J Hum Genet* 2003;11:725–36.
 72. Bottorff JL, Ratner PA, Balneaves LG, *et al.* Women's interest in genetic testing for breast cancer risk: the influence of sociodemographics and knowledge. *Cancer Epidemiol Biomarkers Prev* 2002;11:89–95.
 73. Braithwaite D, Sutton S, Steggle N. Intention to participate in predictive genetic testing for hereditary cancer: the role of attitude toward uncertainty. *Psychol Health* 2002;17:761–72.
 74. National Cancer Institute (NCI) and the National Surgical Adjuvant Breast and Bowel Project (NSABP). *The breast cancer risk assessment tool 3.0*: U.S. Department of Health and Human Services, 2011.
 75. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. *Am J Hum Genet* 1995;56:265.
 76. Evans C, Hamilton RJ, Tercyak KP, *et al.* Understanding the needs of young women regarding breast cancer risk assessment and genetic testing: convergence and divergence among patient-counselor perceptions and the promise of peer support. *Healthcare* 2016;4:35.
 77. Ahmad S, Fergus K, McCarthy M. Psychosocial issues experienced by young women with breast cancer: the minority group with the majority of need. *Curr Opin Support Palliat Care* 2015;9:271–8.
 78. Gouvernement du Québec - Commission de l'éthique en science et en technologie. *Soins de santé personnalisés: document de consultation Québec*. 44, 2012.
 79. McClellan KA, Avard D, Simard J, *et al.* Personalized medicine and access to health care: potential for inequitable access? *Eur J Hum Genet* 2013;21:143–7.
 80. Gail MH. Twenty-five years of breast cancer risk models and their applications. *J Natl Cancer Inst* 2015;107:djv042.
 81. Fisher RA. *Statistical methods and scientific inference*, 1956.
 82. Lipsey MW. *Design sensitivity: statistical power for experimental research*: Sage, 1990.
 83. Noymer A. Alpha, significance level of test. *Encyclopedia of survey research methods*. 18, 2008.